Pfizer (Essential Health / Injectable Opioids)(PFE)
HQ US75% share
pharmaceutical · input
Pneumococcal Conjugate Vaccine (PCV13/PCV20)
Polysaccharide-protein conjugate vaccines protecting against Streptococcus pneumoniae — the bacterium causing bacterial pneumonia, meningitis, sepsis, and otitis media. CDC schedules PCV for all US infants (4-dose series) and adults 65+. Pfizer Prevnar 13 held ~95% US market share for a decade; Prevnar 20 now expanding adult coverage. Second source: Merck Vaxneuvance (PCV15) entered market 2021.
0
Source countries
3
Companies
1
Goods affected
0
Claims on record
What depends on it
Goods that need this input
1 essential American goods rely on pneumococcal conjugate vaccine (pcv13/pcv20) somewhere upstream in their supply chain.
Who makes it
Supplier companies
3 companies produce pneumococcal conjugate vaccine (pcv13/pcv20).
Merck & Co. (MSD)
HQ US35% share
US pharma/vaccine maker (MSD ex-US); Vaxneuvance PCV15, the second US pneumococcal conjugate vaccine.
Serum Institute of India
HQ IN22% share
World's largest vaccine manufacturer by dose volume — ~1.9–2.0 billion doses/year as of 2023, representing ~60% of global vaccine production. Produces routine childhood vaccines (polio, measles, DTP, BCG), COVID vaccines, and others for Gavi-eligible markets. Single-site concentration risk in Pune.